Products
Technologies
Applications
Services
Resources
Selection Guides
About
PacBlue Anti-human CD16 Antibody
3G8
The 3G8 monoclonal antibody recognizes human CD16a, a 50 - 65 kD transmembrane protein typically found on the surface of macrophages, natural killer cells, dendritic cells, monocytes and neutrophils. CD16 is a member of key cellular pathways, namely, the Fc-gamma receptor signaling pathway involved in phagocytosis. From a research standpoint, it is of biological interest due to its association with important macromolecules/ligands like IgG Fc. CD16 is a very popular antibody target, with over 25000 publications in the last decade. CD16a is frequently used in flow cytometry applications as a phenotypic marker for differentiation of cell types, particularly in the study of immunology. This antibody was purified through affinity chromatography and conjugated to PacBlue (ex/em = 404/455 nm). It is compatible with the 405 nm laser and 460/22 nm bandpass filter (for example, as in the Bio-Rad ZE5 Cell Analyzer).
| Catalog | Size | Price | Quantity |
|---|---|---|---|
| 101611J0 | 100 tests | Price | |
| 101611J1 | 500 tests | Price |
Antibody properties
| Other names | FCRIIIA |
| Clone | 3G8 |
| Host | mouse |
| Reactivity | human |
| Application | Flow Cytometry (FACS); Fluorescence Imaging |
Spectral properties
| Correction factor (260 nm) | 0.15 |
| Correction factor (280 nm) | 0.2 |
| Extinction coefficient (cm -1 M -1) | 46000 |
| Excitation (nm) | 404 |
| Emission (nm) | 455 |
| Quantum yield | 0.78 |
Storage, safety and handling
| H-phrase | H303, H313, H333 |
| Hazard symbol | XN |
| Intended use | Research Use Only (RUO) |
| R-phrase | R20, R21, R22 |
Contact us
| Telephone | |
| Fax | |
| sales@aatbio.com | |
| International | See distributors |
| Bulk request | Inquire |
| Custom size | Inquire |
| Technical Support | Contact us |
| Request quotation | Request |
| Purchase order | Send to sales@aatbio.com |
| Shipping | Standard overnight for United States, inquire for international |
Page updated on December 7, 2025